Summary of Orchestra BioMed FY Conference Call Company Overview - **Company**: Orchestra BioMed (NasdaqGM:OBIO) - **Focus**: Biomedical innovation with two pivotal stage cardiovascular programs: - **Virtue Sirolimus AngioInfusion Balloon** for coronary artery disease - **Atrioventricular Interval Modulation (AVIM) therapy** for hypertensive heart disease in high-risk patients, partnered with Medtronic [7][36] Key Programs and Developments Virtue Sirolimus AngioInfusion Balloon - **Current Status**: Enrolling pivotal trials, with expectations to finish the BACKBEAT trial this year and data anticipated shortly thereafter [8] - **Market Potential**: Positioned in an almost $8 billion market, with a paradigm shift from drug-eluting stents to drug-eluting balloons [18][19] - **Competitive Landscape**: Currently, only Boston Scientific has a commercial coronary drug-coated balloon in the U.S. [18] - **Clinical Advantage**: Virtue aims to deliver better clinical results with a proprietary drug delivery method that encapsulates sirolimus, leading to significantly higher drug levels compared to existing products [25][26] Atrioventricular Interval Modulation (AVIM) Therapy - **Trial Progress**: Enrollment is accelerating with over 100 sites engaged, and protocol changes have improved participation [38] - **Therapeutic Impact**: AVIM therapy shows immediate blood pressure reduction in patients, with significant double-digit drops observed [40][41] - **Market Opportunity**: Estimated 1 million patients worldwide receiving pacemakers annually could benefit from AVIM therapy [42] - **Regulatory Path**: Medtronic is responsible for regulatory and manufacturing aspects, with a focus on U.S. market approval expected around 2028 [51][54] Financial and Strategic Partnerships - **Recent Financing**: Secured over $60 million from partners including Medtronic and Terumo, minimizing equity dilution and providing a strong balance sheet [14][15] - **Business Model**: Focused on leveraging strategic partnerships for commercialization, with significant royalty interests from products [7] Market Dynamics and Clinical Insights - **Physician Engagement**: High enthusiasm from physicians regarding the unique delivery method of Virtue and the potential clinical advantages [34] - **Clinical Data**: Ongoing education for physicians about the differences between sirolimus and paclitaxel, emphasizing the benefits of sirolimus in healing vessels [33] - **Hypertension and Heart Failure**: AVIM therapy targets a unique patient population with uncontrolled systolic hypertension, potentially impacting quality of life and cardiac function [60][63] Conclusion - **Outlook**: Orchestra BioMed is well-positioned for future growth with innovative products addressing significant market needs, strong partnerships, and a clear path towards commercialization [36][64]

Three snipers bought 628.83M $AGENT(62.88% of the supply) with 8.8 $BNB($5,628) right after launch.They later sold 570.12M $AGENT for 610 $BNB($390K) and still hold 58.7M $AGENT($106K).Total profit: $490K— an 87x return!https://t.co/MLPfP2jJ1Fhttps://t.co/LvyocIWeOehttps://t.co/bJEFK1TSbJ ...

Boston Scientific Conference Call Summary Company Overview - **Company**: Boston Scientific - **Analyst**: Robbie Marcus, MedTech Analyst at J.P. Morgan - **Key Executives Present**: Mike Mahoney (CEO), Jon Monson (CFO), Dr. Stein (Chief Medical Officer) Key Industry Insights Market Growth and Product Launches - Boston Scientific is committed to achieving **10%+ growth** over the next three years and **150 basis points of margin improvement** [2] - The company anticipates an increase in the weighted average market growth rate from **8% in 2025 to 9%** over the next three years [2] - The **Pulsed Field Ablation (PFA)** market is projected to grow at a minimum of **15%+** annually, with the overall market growth reaching **20%** in 2025 [4][10] Product Highlights - **Pulsed Field Ablation**: Recognized as a leading product in the medtech market, with significant market share and growth potential [4] - **FARAPOINT**: Recently approved for use in the U.S. and Europe, expected to enhance the portfolio for arrhythmias and expand into non-AF ablations [11][18] - **Watchman**: Holds a **91% market share** in left atrial appendage closure (LAAC), with potential for growth in concomitant procedures [28][30] Competitive Landscape - Boston Scientific's leadership in the PFA market is attributed to strong execution and a comprehensive product pipeline [6] - The company emphasizes the importance of having a complete toolset for electrophysiology (EP) procedures, which includes various catheter types and access solutions [11][19] Financial Performance and Projections Revenue and Market Position - The company is confident in its ability to meet investor day targets and has consistently delivered on commitments [26] - Anticipated growth in the **interventional oncology** and **vascular therapies** divisions, with ongoing trials and product launches expected to drive revenue [40][42] Pricing Strategy - Boston Scientific aims to maintain flat pricing, with expectations of slight declines in certain markets due to competitive pressures [64] - The company has improved its pricing strategy, targeting flat pricing after previously facing headwinds [61] Strategic Initiatives Innovation and R&D - Boston Scientific invests heavily in both internal and external innovation, with a focus on maintaining a strong pipeline and venture portfolio [56][57] - The company is committed to improving operational efficiency, with ongoing initiatives in AI and ERP systems to enhance productivity [62] Market Expansion - The company is optimistic about growth in **China**, projecting sustainable growth in the teens despite market challenges [66] - Boston Scientific is also exploring opportunities in the **ASC (Ambulatory Surgery Center)** market to increase patient volumes and lab capacity [14][15] Additional Insights Clinical Trials and Future Opportunities - The **AVANT GUARD trial** aims to establish catheter ablation as a first-line therapy for persistent atrial fibrillation, with results expected to influence future treatment protocols [21] - The company is exploring the use of its products in various clinical settings, including potential applications for ventricular tachycardia and redo ablations [18][19] Conclusion - Boston Scientific is well-positioned for continued growth with a robust product pipeline, strong market leadership, and a commitment to innovation and operational efficiency. The company is focused on leveraging its competitive advantages in the medtech space to drive future success.

Financial Data and Key Metrics Changes - In Q3 2025, total company operational sales grew 19%, and organic sales grew 15%, exceeding the guidance range of 12%-14% [6][22] - Q3 adjusted EPS was $0.75, reflecting a 19% increase and surpassing the guidance range of $0.70-$0.72 [6][22] - Adjusted operating margin for Q3 was 28%, with an expectation to expand full-year adjusted operating margin by approximately 100 basis points [6][23][26] Business Line Data and Key Metrics Changes - Urology sales grew 27% operationally and 5% organically, driven by international business and Global Stone Management [9] - Endoscopy grew 9%, with double-digit growth in key products [10] - Neuromodulation sales increased by 9%, supported by strong performance in the brain franchise [10] - Peripheral interventions sales grew 16% operationally and 6% organically, with low double-digit growth in the U.S. [11] - Cardiology sales grew 23%, with interventional cardiology therapy sales growing 3% [14] Market Data and Key Metrics Changes - U.S. operational sales grew 27%, while Europe, Middle East, and Africa (EMEA) declined 2% due to specific headwinds [7][8] - Asia-Pacific grew 17% operationally, led by strong growth in Japan and China [8] - WATCHMAN sales grew 35%, reflecting strong market penetration and adoption [15][16] Company Strategy and Development Direction - The company is focused on strategic tuck-in M&A in high-growth adjacencies, with the recent agreement to acquire Nalu Medical to expand into peripheral nerve pain [11][24] - The company aims for 10%+ average organic revenue growth from 2026 to 2028, with a target of 70%-80% annual free cash flow conversion [28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining above-market growth, with expectations for continued strong performance in the cardiovascular and MedSurg segments [6][7] - The company anticipates improvements in backorders and operational performance in Europe in the fourth quarter [8] - Management remains optimistic about the growth potential of WATCHMAN and electrophysiology, projecting a 20% CAGR over the long-range plan [32][48] Other Important Information - The company experienced a backorder of approximately $30 million due to an ERP system upgrade, impacting various business lines [8][76] - The company expects to close the acquisition of Nalu Medical in the first half of 2026 [11][24] Q&A Session Summary Question: Is WATCHMAN a key growth driver? - Management confirmed that WATCHMAN is a significant growth driver, with expectations for continued market expansion and strong performance [32] Question: What is the outlook for the China market? - Management indicated that the China business is performing well, with expectations for double-digit growth despite price pressures [39] Question: How will the new product cycle impact CRM growth? - Management expressed confidence in the upcoming product cycle, including the Denali platform and EMPOWER leadless pacemaker, to strengthen CRM growth [86] Question: What are the dynamics outside EP and WATCHMAN? - Management highlighted strong growth in other divisions, including neuromodulation and endoscopy, and emphasized ongoing investments in these areas [58]